2024-02-22Zeitschriftenartikel
Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024
Maurel, Marine; Howard, Jennifer; Kissling, Esther; Pozo, Francisco; Pérez-Gimeno, Gloria; Buda, Silke; Sève, Noémie; McKenna, Adele; Meijer, Adam; Rodrigues, Ana Paula; Martínez-Baz, Iván; Mlinarić, Ivan; Latorre-Margalef, Neus; Túri, Gergő; Lazăr, Mihaela; Mazagatos, Clara; Echeverria, Aitziber; Abela, Stephen; Bourgeois, Marc; Machado, Ausenda; Dürrwald, Ralf; Petrović, Goranka; Beatrix; Oroszi, Beatrix; Jancoriene, Ligita; Marin, Alexandru; Husa, Petr; Duffy, Roisin; Dijkstra, Frederika; Gallardo García, Virtudes; Goerlitz, Luise; Enouf, Vincent; Bennett, Charlene; Hooiveld, Mariëtte; Guiomar, Raquel; Trobajo-Sanmartín, Camino; Višekruna Vučina, Vesna; Samuelsson Hagey, Tove; Lameiras Azevedo, Ana Sofía; Castilla, Jesús; Xuereb, Gerd; Delaere, Bénédicte; Gómez, Verónica; Tolksdorf, Kristin; Bacci, Sabrina; Nicolay, Nathalie; Kaczmarek, Marlena; Rose, Angela M. C.; on behalf of the European IVE group
Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, ...
